Gabaergic Mutants

GABAergic mutants are organisms carrying genetic changes that alter gamma-aminobutyric acid (GABA) signaling, providing a way to study how inhibitory neurotransmission shapes nervous-system function. These mutations can affect GABA synthesis, transport, release, or receptor activity; for example, disrupting glutamate decarboxylase reduces GABA production, while receptor changes modify the neuronal response to GABA-mediated chloride conductance. Researchers use these mutants to analyze neural circuits, synaptic inhibition, movement, behavior, and seizure-related phenotypes. Comparing mutant and normal organisms helps link specific genes to neuronal communication and can reveal mechanisms relevant to neurological disease and potential therapeutic strategies.

Gabaergic Mutants - Related Videos

Research

JoVE Journal - Biology

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

0 Views •

Cited by 20 •

2008

This video demonstrates how to employ two neural stimulants, aldicarb and pentylenetetrazole (PTZ), in complementary ways to study synaptic function in the nematode, C. elegans. This complementary approach may also be used to shed light on evolutionarily conserved mechanisms for modulating neuronal synchrony and has implications for epilepsy and seizures.

Education

JoVE Core - Pharmacology

Antiepileptic Drugs: GABAergic Pathway Potentiators

0 Views •

2024

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures. The key GABA pathway potentiators used in epilepsy management are as follows. Benzodiazepines are a well-known class of drugs used for their...

Research

JoVE Journal - Medicine
Free Sample

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease

0 Views •

2025

This protocol details a quantitative defecation assay in young RAC1/CED-10 mutant Caenorhabditis elegans, providing a straightforward model to study prodromal Parkinson's disease stages. It overcomes limitations of other animal models and facilitates testing of therapeutic strategies targeting early Parkinsonian pathology.

Generation of Maternal Mutants Using zpc:cas9 Knock-in Zebrafish

0 Views •

2025

Here, we describe a protocol for generating maternal mutant that couples a stable zpc:cas9 knock-in line with Tol2-mediated delivery of sgRNA expression cassettes.

Expansion of Mutant Vaccinia Virus in Mammalian Cells

0 Views •

2026

Source: Yuan, M., et al. A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors. J. Vis. Exp. (2016)This video demonstrates the expansion of plaque-derived recombinant virus in adherent mammalian cells. The virus carries a fluorescent reporter in place of a virulent gene, enabling infection tracking. Infected cells are harvested for PCR verification of the genetic modification.

View All Results

FAQs

Related Topics